An AI system is granted full regulatory approval to independently diagnose and prescribe treatment without doc

Question

Six frontier AI models put this at 16% by 17 Sept 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

16% — the median of 6 frontier models, resolving by 2036-09-17.

Answer

Gemini (Google): 27% — Strict liability laws and fierce resistance from physician lobby groups make regulators reluctant to remove the doctor from the loop. FDA De Novo clearance for autonomous screening already exists (IDx-DR), but autonomous prescription requires reshaping state medical boards. Developing narrow indications like uncomplicated UTIs could clear trials by 2030, yet statutory pharmacy rules mandate human prescribers. A catastrophic misdiagnosis liability ruling would freeze rulemaking, whereas approval by the UK MHRA or EMA is the fastest path.

Answer

Claude (Anthropic): 13% — Turns on whether FDA/EMA creates a wholly new autonomous-practice pathway, not just AI-as-tool clearances. FDA's current framework (510(k), De Novo) treats AI as a device requiring clinician oversight, and no proposed rule changes this structurally. Legal liability, malpractice law, and medical licensing statutes in most jurisdictions require a licensed human prescriber, a much higher bar than regulatory clearance… 10-year window allows for incremental narrow-domain approvals (e.g. diabetic retinopathy autonomous diagnosis already exists), but full independent…

Answer

GPT (OpenAI): 24% — This hinges on whether regulators accept AI as the legally accountable prescriber, not merely a supervised clinical tool. The FDA can clear software as a device, but U.S. prescribing law currently requires a licensed clinician with professional accountability. Autonomous diagnosis has narrow precedents, such as FDA-cleared diabetic-retinopathy screening, but none can prescribe or manage broad treatment. Odds rise sharply if Congress or state boards create an AI-prescriber license after strong real-world safety data before 2036.

Answer

Grok (xAI): 18% — FDA/EMA-class approval of fully autonomous Rx authority by 2032 hinges on new liability law plus pivotal trials that do not yet exist. No regulator has ever authorized an AI to prescribe; IDx-DR (2018) remains the only autonomous diagnostic and covers one condition with no Rx. Class-III PMA plus enabling statutes on malpractice and pharmacy dispensing typically take 8–12 years after first large RCT; none have started. A 2027–28 Chinese or Gulf fast-track or US AI-liability bill would be the only development that could lift this above ~25.

Answer

DeepSeek (DeepSeek): 7% — No regulator has even a draft pathway for autonomous prescribing; the FDA's current posture is assistive-only. The FDA's 2021 AI/ML SaMD action plan and every cleared device to date require a clinician in the loop; no autonomous prescribing pathway exists. Prescribing is a licensed-practitioner act under state medical boards and DEA rules, so approval would need statutory change, not just FDA clearance. Diagnostic autonomy is nearer (autonomous retinopathy screening exists), but prescribing authority is a separate legal category with no precedent.

Answer

Qwen (Alibaba): 3% — Full autonomous prescribing without any human oversight faces regulatory, liability, and political barriers that won't clear by 2032. FDA's current framework (SaMD, De Novo, 510(k)) has never approved fully autonomous prescribing; even IDx-DR (2018) only covers diabetic retinopathy screening, not… Medical malpractice liability requires a human defendant; no US state legislature or major regulator will create a legal framework for AI-only prescribing within 6 years. The one development that would change this: a small jurisdiction (e.g., Rwanda, UAE) granting narrow autonomous authority for a single condition in an access-crisis…

An AI system is granted full regulatory approval to independently diagnose and prescribe treatment without doctor oversight by 2032.

What each one said

An AI system is granted full regulatory approval to independently diagnose and prescribe treatment without doctor oversight by 2032.

A universal or broadly curative therapy for most major cancer types is approved before 2035.

AbbVie submits a regulatory filing for etentamig based on the Phase 3 CERVINO study.

The FDA withdraws marketing approval for Amgen's Tavneos.

Indonesian health ministry reports show another week-on-week increase in respiratory infections from wildfires in the next official update.